UK markets closed

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.5670-0.0070 (-1.22%)
At close: 03:46PM GMT
Full screen
Loading interactive chart…
  • Globe Newswire

    Santhera Calls Extraordinary General Meeting to Seek Approval for Further Financings

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 4, 2022 – Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General Meeting (EGM), which will be held on November 29, 2022, at 10:30 hrs at the domicile of the Company. At the EGM, Santhera seeks authorization for additional funding to enable continued pipeline development and preparations for the commercialization of vamorolone. Funding OutlookAs announced earlier,

  • Globe Newswire

    European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, October 31, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Validation confirms that the submission is complete and that the review by the EMA’s Committee for Medicinal Products for Human Use (CHMP) has begun. “The initiation of the CHMP review of our application is an important milestone for patie

  • Globe Newswire

    Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update

    Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on November 7, 2022, at 14:30 CET, 13:30 GMT, 08:30 EST. Details are at the end of this news release. Revenue from contracts with customers of CHF 6.3 million (H1-2021: CHF 4.5 million)Operating result of CHF -25.5 million (H1-2021: CHF -19.5 million) and net result of CHF -29.7 million (H1-2021: CHF -20.5 million)Cash and cash equivalents of CHF 12.7 million (June 30, 2022), together with existing facilities enabling cash